PMID- 38375055
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240221
IS  - 2589-3610 (Electronic)
IS  - 1674-6384 (Print)
IS  - 1674-6384 (Linking)
VI  - 16
IP  - 1
DP  - 2024 Jan
TI  - Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer 
      cells by targeting PI3K/AKT/mTOR and EMT pathways.
PG  - 94-105
LID - 10.1016/j.chmed.2023.01.004 [doi]
AB  - OBJECTIVE: This study is designed to investigate the mode of action of the 
      synergistic effect of 5-fluorouracil (5-FU) and magnolol against cervical cancer. 
      METHODS: Network pharmacological approach was applied to predict the molecular 
      mechanism of 5-FU combined with magnolol against cervical cancer. CCK-8 assay, 
      colony formation assay, immunofluorescence staining, adhesion assay, wound 
      healing mobility assay, cell migration and invasion assay and Western blot 
      analysis were conducted to validate the results of in silico study. RESULTS: 
      Phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of 
      rapamycin (mTOR) signaling pathway was identified as the key pathway in silico 
      study. The experimental results showed that 5-FU combined with magnolol strongly 
      inhibited cervical cancer cell proliferation, induced the morphological change of 
      HeLa cells by down-regulating the expression of alpha-actinin, tensin-2 and vinculin. 
      Moreover, magnolol enhanced inhibitory effect of 5-FU on the cell adhesion, 
      migration and invasion. The phosphorylation of AKT and PI3K and the expression of 
      mTOR were strongly inhibited by the combination of 5-FU and magnolol. Moreover, 
      the expression of E-cadherin and beta-catenin was upregulated and the expression of 
      Snail, Slug and vimentin was down-regulated by the 5-FU together with magnolol. 
      CONCLUSION: Taken together, this study suggests that 5-FU combined with magnolol 
      exerts a synergistic anti-cervical cancer effect by regulating the PI3K/AKT/mTOR 
      and epithelial-mesenchymal transition (EMT) signaling pathways.
CI  - (c) 2023 Tianjin Press of Chinese Herbal Medicines. Published by ELSEVIER B.V.
FAU - Chen, Yuanyuan
AU  - Chen Y
AD  - Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for 
      Prevention and Treatment of Senile Diseases, Medical College of Yangzhou 
      University, Yangzhou 225009, China.
FAU - Chen, Shanshan
AU  - Chen S
AD  - Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for 
      Prevention and Treatment of Senile Diseases, Medical College of Yangzhou 
      University, Yangzhou 225009, China.
FAU - Chen, Kaiting
AU  - Chen K
AD  - Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for 
      Prevention and Treatment of Senile Diseases, Medical College of Yangzhou 
      University, Yangzhou 225009, China.
FAU - Ji, Lanfang
AU  - Ji L
AD  - Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for 
      Prevention and Treatment of Senile Diseases, Medical College of Yangzhou 
      University, Yangzhou 225009, China.
FAU - Cui, Shuna
AU  - Cui S
AD  - Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for 
      Prevention and Treatment of Senile Diseases, Medical College of Yangzhou 
      University, Yangzhou 225009, China.
AD  - Department of Gynecology and Obstetrics, Affiliated Hospital of Yangzhou 
      University, Yangzhou 225009, China.
LA  - eng
PT  - Journal Article
DEP - 20230525
PL  - Singapore
TA  - Chin Herb Med
JT  - Chinese herbal medicines
JID - 101556727
PMC - PMC10874772
OTO - NOTNLM
OT  - 5-fluorouracil
OT  - EMT pathway
OT  - PI3K/AKT/mTOR pathway
OT  - cervical cancer
OT  - magnolol
OT  - network pharmacology
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2024/02/20 11:51
MHDA- 2024/02/20 11:52
PMCR- 2023/05/25
CRDT- 2024/02/20 03:38
PHST- 2022/10/06 00:00 [received]
PHST- 2022/11/29 00:00 [revised]
PHST- 2023/01/16 00:00 [accepted]
PHST- 2024/02/20 11:52 [medline]
PHST- 2024/02/20 11:51 [pubmed]
PHST- 2024/02/20 03:38 [entrez]
PHST- 2023/05/25 00:00 [pmc-release]
AID - S1674-6384(23)00054-0 [pii]
AID - 10.1016/j.chmed.2023.01.004 [doi]
PST - epublish
SO  - Chin Herb Med. 2023 May 25;16(1):94-105. doi: 10.1016/j.chmed.2023.01.004. 
      eCollection 2024 Jan.